Brief: CytRx Corp Highlights Positive Results From Phase 2/3 Clinical Trial In Niemann Pick Disease Type C (Npc)

LadRx

06/02/2019 14:10

Feb 6 (Reuters) - CytRx Corp  CYTR.O :
    * CYTRX CORPORATION HIGHLIGHTS POSITIVE RESULTS FROM FULL
DATA SET
OF PHASE 2/3 CLINICAL TRIAL IN NIEMANN PICK DISEASE TYPE C (NPC)
CONDUCTED BY ARIMOCLOMOL LICENSEE ORPHAZYME A/S
    * CYTRX CORP - CYTRX ELIGIBLE TO RECEIVE UP TO $120 MILLION
IN
FUTURE MILESTONES, PLUS ROYALTIES, FROM ARIMOCLOMOL LICENSING
AGREEMENT
    * CYTRX CORP - ORPHAZYME TO ENGAGE WITH FDA AND EMA ON PATH
TO
APPROVAL WHILE PREPARING FOR FILING
    * CYTRX CORP - ORPHAZYME COMMUNICATED THAT IT PLANS TO
SUBMIT
REGULATORY FILING TO FDA AND EMA DURING FIRST HALF OF 2020
    * CYTRX CORP - IN FULL DATA SET ANALYSIS, TREATMENT WITH
ARIMOCLOMOL ADJUNCT TO ROUTINE CLINICAL CARE RESULTED IN A 74%
REDUCTION IN DISEASE PROGRESSION

Source text for Eikon:  ID:nPnbqMvx4a 
Further company coverage:  CYTR.O 

 ((Reuters.Briefs@thomsonreuters.com;))